An Oral Galectin Inhibitor in COVID-19—A Phase II Randomized Controlled Trial

Background: SARS-CoV-2 vaccines play an important role in reducing disease severity, hospitalization, and death, although they failed to prevent the transmission of SARS-CoV-2 variants. Therefore, an effective inhibitor of galectin-3 (Gal-3) could be used to treat and prevent the transmission of COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Sigamani, Alben, Mayo, Kevin H., Miller, Michelle C., Chen-Walden, Hana, Reddy, Surendar, Platt, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140888/
https://www.ncbi.nlm.nih.gov/pubmed/37112643
http://dx.doi.org/10.3390/vaccines11040731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140888/
https://www.ncbi.nlm.nih.gov/pubmed/37112643
http://dx.doi.org/10.3390/vaccines11040731

Ejemplares similares